ニュース、リソース、最新情報
当社の最新の研究動向や企業情報をお届けする科学情報拠点です。
神経変性疾患の研究モデルから最大限の価値を引き出すには？
To date, large ongoing efforts are being made to provide well-characterised animal models which are suitable for investigating novel therapeutics. To ensure full confidence in the efficacy profile of novel therapeutic agents, efficacy testing often needs to be...
InnoSer、AD/PD 2024で、in vitroにおける神経変性疾患のモデル化能力を示す新たなデータを発表へ
We are thrilled to announce that InnoSer, as an innovative preclinical contract research organization (CRO), will be actively participating in the upcoming AD/PD 2024 Conference taking place in Lisbon, Portugal on March 5-9, 2024. The theme of AD/PD 2024 is striving...
研究において生物発光イメージングを最大限に活用する
The application of bioluminescence imaging (BLI) in preclinical research studies offers quantitative, sensitive, longitudinal real-time data and can be applied in: Validation of cancer cell lines, helping to establish improved preclinical cancer mouse models. ...
ADPKDマウスモデルにおける嚢胞指数の応用
The kidneys of autosomal dominant polycystic kidney disease (ADPKD) patients progressively enlarge due to the formation and expansion of fluid-filled cysts. However, currently there is no available therapy for ADPKD patients that targets the growth of cysts,...
前臨床研究において腎機能のトランスレーショナルな測定値を組み込むことの重要性：経皮的GFR測定
Preclinical Nephrology Research Preclinical studies aiming to assess kidney function in animal models of kidney disease or in response to a test compound have traditionally included readouts such as serum creatinine and blood urea nitrogen (BUN). However, the use of...
白質萎縮におけるeIF2Bモジュレーター
Vanishing White Matter (VWM) disease is a rare and fatal leukodystrophy, caused by recessive mutations in the five genes encoding the protein complex eukaryotic translation initiation factor 2B (eIF2B). eIF2B plays a crucial role in initiating and regulating the...
info@innoserlaboratories.com